the interleukin-2 mutein utilized in this clinical trial ( des-ala-ser125 r-il-2 ) differs from the major species of the human t cell-derived lymphokine in that it lacks the n-terminal alanine of the native molecule , is not glycosylated , and possesses a serine-cysteine substitution at position 125 .
C0021756
il-2
C0086418
human